within Pharmacolibrary.Drugs.ATC.N;

model N01AX05_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.000395,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00099,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00127,
    k12             = 24.7,
    k21             = 24.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N01AX05_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alfaxalone is a neuroactive steroid anesthetic agent, used for induction and maintenance of anesthesia primarily in veterinary medicine for dogs and cats; not approved for human use. It potentiates the effects of GABA at GABA-A receptors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult beagle dogs after single intravenous bolus injection of 2 mg/kg.</p><h4>References</h4><ol><li><p>Dehuisser, V, et al., &amp; Polis, I (2019). Alfaxalone total intravenous anaesthesia in dogs: pharmacokinetics, cardiovascular data and recovery characteristics. <i>Veterinary anaesthesia and analgesia</i> 46(5) 605–612. DOI:<a href=\"https://doi.org/10.1016/j.vaa.2019.04.014\">10.1016/j.vaa.2019.04.014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31395484/\">https://pubmed.ncbi.nlm.nih.gov/31395484</a></p></li><li><p>Wakuno, A, et al., &amp; Ohta, M (2019). Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. <i>The Veterinary record</i> 184(13) 411–None. DOI:<a href=\"https://doi.org/10.1136/vr.105070\">10.1136/vr.105070</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30926700/\">https://pubmed.ncbi.nlm.nih.gov/30926700</a></p></li><li><p>Rodrigo-Mocholí, D, et al., &amp; Marín, P (2018). Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. <i>New Zealand veterinary journal</i> 66(4) 172–177. DOI:<a href=\"https://doi.org/10.1080/00480169.2018.1455541\">10.1080/00480169.2018.1455541</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29562829/\">https://pubmed.ncbi.nlm.nih.gov/29562829</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N01AX05_1;
